Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

319.73 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19
Open 319.73
Bid (Size) 315.70 (1)
Ask (Size) 323.99 (1)
Prev. Close 319.73
Today's Range 319.73 - 319.73
52wk Range 249.70 - 346.85
Shares Outstanding N/A
Dividend Yield 2.66%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill
Amgen faces a class-action lawsuit over allegations of concealing a $10.7 billion tax dispute with the IRS, with shareholders accusing the company of delaying critical disclosures. A federal judge... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga

Performance

YTD
+7.51%
+7.51%
1 Month
-3.26%
-3.26%
3 Month
+3.35%
+3.35%
6 Month
+16.51%
+16.51%
1 Year
+22.50%
+22.50%

More News

Read More
AskSlim Market Week - Friday, Sep. 27
Via Talk Markets
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Analyst Expectations For Amgen's Future
Via Benzinga
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
What the Options Market Tells Us About Amgen
Via Benzinga
Interesting Technical Analysis finding for AMGEN INC (NASDAQ:AMGN)
Via Chartmill
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Via Investor's Business Daily
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Via Benzinga
Where Will Amgen Be in 5 Years?
Via The Motley Fool
Behind the Scenes of Amgen's Latest Options Trends
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Via Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
Via The Motley Fool
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
Via Investor's Business Daily
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
Via The Motley Fool
Can These 5 Assets Skyrocket Your Portfolio?
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Bull Market Strengthened, Let The Naysayers Say Nay...
Via Talk Markets
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500
Via The Motley Fool
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.